Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Single Dose Nemiralisib in Healthy Participants
NCT03189589Phase 1Completed
- Sponsor
- GSK
- Start
- Jun 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nemiralisib in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoints: Mean GSK2269557 Plasma Concentration at Day 6, Area Under the Plasma Drug Concentration Versus Time Curve at Day 6 and 3 more. Started Jun 2017; status: completed.
02
Drugs
nemiralisib
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03189589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189589.